COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: COL-3 may stop the growth of brain tumors by stopping blood flow to the tumor.
PURPOSE: Phase I/II trial to study the effectiveness of COL-3 in treating patients who have
progressive or recurrent brain tumors following radiation therapy or chemotherapy.